Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

1368609

USP

Lisinopril

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

1-[N2-((S)-1-Carboxy-3-phenylpropyl)-L-lysyl]-L-prolin Dihydrat, MK-521

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

300 MG
CHF 391.00

CHF 391.00

Voraussichtliches Versanddatum17. April 2025

Bulk-Bestellung anfordern
Alle Fotos(1)

Größe auswählen

Ansicht ändern
300 MG
CHF 391.00

About This Item

Empirische Formel (Hill-System):
C21H31O5N3 · 2H2O
CAS-Nummer:
83915-83-7
Molekulargewicht:
441.52
MDL-Nummer:
MFCD01698825
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329750250
NACRES:
NA.24

CHF 391.00

Voraussichtliches Versanddatum17. April 2025

Bulk-Bestellung anfordern

Qualität

pharmaceutical primary standard

API-Familie

lisinopril

Hersteller/Markenname

USP

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

SMILES String

[H]O[H].[H]O[H].NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O

InChI

1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1

InChIKey

CZRQXSDBMCMPNJ-ZUIPZQNBSA-N

Angaben zum Gen

human ... ACE(1636)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Lisinopril USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Lisinopril and Hydrochlorothiazide Tablets
  • Lisinopril Compounded Oral Suspension
  • Lisinopril Tablets

Biochem./physiol. Wirkung

Hemmstoff des Angiotensin-konvertierenden Enzyms (Angiotensin converting enzyme (ACE))

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

L0702000

Lisinopril Dihydrat, European Pharmacopoeia (EP) Reference Standard

Y0001234

Lisinopril Unreinheit F, European Pharmacopoeia (EP) Reference Standard

Y0001701

Lisinopril für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard

Y0001709

Lisinopril für die Systemeignung A, European Pharmacopoeia (EP) Reference Standard

1368610

Lisinopril-verwandte Verbindung A, United States Pharmacopeia (USP) Reference Standard

BP695

Lisinopril Dihydrat, British Pharmacopoeia (BP) Reference Standard

PHR2239

Lisinopril-Unreinheit A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2495

Lisinopril-Unreinheit B, Pharmaceutical Secondary Standard; Certified Reference Material

Piktogramme

Health hazard
GHS08

Signalwort

Danger

H-Sätze

H360D,H373

Gefahreneinstufungen

Repr. 1A - STOT RE 2

Zielorgane

Kidney

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Stephen J Bright et al.
Australasian journal on ageing, 34(1), 33-37 (2013-10-15)
The Alcohol-Related Problems Survey (ARPS) reliably classifies drinking as non-hazardous, hazardous or harmful using scoring algorithms that consider quantity and frequency of alcohol use alone and in combination with health conditions, medication-use and functional status. Because it has been developed
T D Giles
Zeitschrift fur Kardiologie, 80 Suppl 2, 35-39 (1991-01-01)
Data from the lisinopril-captopril comparison trial (6), as well as other data (1, 8, 14, 10) indicate that both long- and short-acting ACEI are effective and safe for the treatment of CHF. An improved effect on LV function and signs
M C Nzerue
The Central African journal of medicine, 38(9), 391-392 (1992-09-01)
A case of angioedema induced by antihypertensive therapy with lisinopril is presented. The patient was a 70 year old black woman, with a history of hypertension for 15 years. The patient presented with acute onset of swelling involving the oro-facial
H D Langtry et al.
Drugs & aging, 10(2), 131-166 (1997-02-01)
Lisinopril, the lysine analogue of enalaprilat, is a long-acting angiotensin converting enzyme (ACE) inhibitor which is administered once daily by mouth. The efficacy of lisinopril in reducing blood pressure is well established in younger populations, and many trials now show
C Valenzuela et al.
General pharmacology, 25(5), 825-832 (1994-09-01)
1. The effects of lisinopril, an angiotensin-converting enzyme inhibitor, were studied on cardiac contractile force, action potential characteristics and membrane ionic currents. 2. In guinea-pig atria, lisinopril (0.001-1 microM) exerted a negative inotropic effect which was accompanied by a shortening
Alle zugehörigen Dokumente anzeigen

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.